Follow
About Tr1XTr1X is a clinical-stage biotechnology company developing engineered Tr1 cell therapies to restore immune balance in autoimmune and inflammatory diseases. Leveraging the unique biology of Tr1 cells the company is advancing a pipeline of off-the-shelf allogeneic and in vivo C
About Tr1XTr1X is a clinical-stage biotechnology company developing engineered Tr1 cell therapies to restore immune balance in autoimmune and inflammatory diseases. Leveraging the unique biology of Tr1 cells the company is advancing a pipeline of off-the-shelf allogeneic and in vivo C
About Tr1XTr1X is a clinical-stage biotechnology company developing engineered Tr1 cell therapies to restore immune balance in autoimmune and inflammatory diseases. Leveraging the unique biology of Tr1 cells the company is advancing a pipeline of off-the-shelf allogeneic and in vivo C
About Tr1XTr1X is a clinical-stage biotechnology company developing engineered Tr1 cell therapies to restore immune balance in autoimmune and inflammatory diseases. Leveraging the unique biology of Tr1 cells the company is advancing a pipeline of off-the-shelf allogeneic and in vivo C
About Tr1XTr1X is a private clinical-stage biotechnology company focused on developing a novel class of regulatory T cell-based products to cure autoimmune and inflammatory diseases. Founded by industry experts including the scientists who discovered Type 1 regulatory T (Tr1) cells th
About Tr1XTr1X is a private clinical-stage biotechnology company focused on developing a novel class of regulatory T cell-based products to cure autoimmune and inflammatory diseases. Founded by industry experts including the scientists who discovered Type 1 regulatory T (Tr1) cells th
About Tr1XTr1X is a private clinical-stage biotechnology company focused on developing a novel class of regulatory T cell-based products to cure autoimmune and inflammatory diseases. Founded by industry experts including the scientists who discovered Type 1 regulatory T (Tr1) cells th
About Tr1XTr1X is a private clinical-stage biotechnology company focused on developing a novel class of regulatory T cell-based products to cure autoimmune and inflammatory diseases. Founded by industry experts including the scientists who discovered Type 1 regulatory T (Tr1) cells th
